Contents
For professionals
Autoinflammatory conditions: Professional Essentials
An adult-focused clinical orientation: recognize patterns, protect organs and preserve continuity from pediatric to adult care.
On this page
Begin with the inflammatory pattern
An adult with recurrent fever, rash, serositis or unexplained inflammatory markers needs a structured assessment before a rare-disease label. Establish whether inflammation is objectively present, whether episodes are stereotyped, and whether symptoms or laboratory abnormalities persist between attacks. Record onset, attack duration, triggers, organ involvement, family history, ancestry, medicines and response to previous treatment. A childhood history may become apparent only when specifically explored.
Autoinflammation describes inappropriate activation of innate immune pathways; it does not identify a single disease or treatment. Infection, malignancy, drug reactions and other immune-mediated conditions remain active alternatives. A dramatic glucocorticoid response is not diagnostic. Start with the adult assessment chapter.
Choose tests that address a clinical question
Use examination and the time course to select blood counts, inflammatory markers, renal and liver testing, urinalysis and further investigations. Compare findings during an episode and between episodes when feasible. Cultures, imaging, tissue sampling and specialist assessments should follow the suspected organ process or alternative diagnosis. Persistent unexplained cytopenias deserve particular attention.
Ferritin is useful in context but is neither a universal screening answer nor proof of Still’s disease or MAS. Interpret results alongside trends and clinical deterioration. Genetic testing should answer a defined question; a variant of uncertain significance does not establish causality, while a negative panel does not exclude every autoinflammatory disorder.
Recognize inherited disease in an adult clinic
FMF, CAPS, TRAPS and mevalonate kinase deficiency may present to adult services after delayed diagnosis or childhood treatment. Consider attack characteristics, serositis, rash, musculoskeletal symptoms, hearing or neurologic involvement and family history together. Variable expression, reduced penetrance and somatic mosaicism complicate simple genotype-to-phenotype assumptions. Obtain the original molecular report and seek specialist interpretation when the clinical and genetic findings disagree.
In FMF, sustained colchicine treatment aims to control attacks and ongoing inflammation and reduce AA amyloidosis risk. Apparent treatment failure requires assessment of adherence, tolerability, interactions and dose constraints before escalation. Targeted therapy does not make those questions irrelevant. Use the FMF and inherited syndrome chapters for detail.
Identify acquired and adult-onset syndromes
Still’s disease can combine fever, rash, arthritis and systemic inflammation, but exclusion of important mimics remains essential. Current EULAR/PReS recommendations frame adult-onset Still’s disease and systemic juvenile idiopathic arthritis within one disease spectrum, with early control of inflammation and reduction of prolonged glucocorticoid exposure as major goals.
VEXAS is an acquired somatic UBA1-associated disorder, often presenting in later adulthood with inflammation and hematologic abnormalities. Macrocytic anemia, other cytopenias, chondritis, skin disease or thrombosis can prompt joint rheumatology–hematology assessment. Schnitzler syndrome links a chronic urticarial eruption, monoclonal gammopathy and an inflammatory phenotype. The presence of gammopathy alone is insufficient; diagnostic criteria and continuing hematologic surveillance matter.
Keep diagnostic boundaries explicit
Adult PFAPA and undifferentiated autoinflammatory presentations require careful evaluation rather than automatic transfer of pediatric labels. Document what is established, which alternatives remain plausible and what future observation could change the working diagnosis. A treatment response can support management without proving a particular mechanism.
Early onset, unusual infections, strokes, cytopenias, severe ulceration or a striking family history may suggest an immune dysregulation syndrome such as DADA2 or haploinsufficiency of A20. These disorders do not fit a universal IL-1 treatment ladder. Their overlap with vasculitis, Behçet-like disease or immunodeficiency is a reason for specialist collaboration, not for erasing those distinctions. See PFAPA, undifferentiated disease and boundaries.
Recognize MAS and HLH without waiting for certainty
Persistent fever with rapid deterioration, falling blood counts, hepatitis, coagulopathy, increasing ferritin or evolving organ dysfunction requires urgent assessment for MAS/HLH and competing emergencies. A falling platelet count may be concerning even before it crosses a classification threshold. Infection may mimic, trigger or coexist with hyperinflammation.
Arrange urgent hospital-level evaluation and involve the relevant specialties while investigations proceed. Classification criteria developed in systemic JIA and the HScore can inform reasoning but are not universal rule-out tests. Do not postpone escalation while waiting for every criterion or a marrow finding. Treatment depends on the underlying condition, severity and local expertise. The MAS/HLH chapter separates recognition from disease-specific treatment decisions.
In adults, actively consider lymphoma-associated HLH. The urgent work-up and treatment intensity depend on the trigger; a rheumatic MAS regimen is not interchangeable with every adult HLH strategy.
Treat the disease and monitor its consequences
Choose treatment according to the diagnosis, organ risk, evidence and regional prescribing information. Colchicine, IL-1 blockade, IL-6 blockade and other therapies have different indications and limitations; biologics are not interchangeable across this group. Review infection risk, vaccination, baseline safety tests, interactions and the planned monitoring schedule before and during treatment.
Clinical improvement does not necessarily exclude inflammation between attacks. Persistent inflammation can lead to AA amyloidosis in susceptible disorders. Monitor urinary protein and renal function where indicated; serum amyloid A may help when available. New proteinuria requires investigation rather than automatic attribution to amyloid. Reassess apparent refractory disease for an incorrect diagnosis, inadequate exposure, toxicity, organ damage or a second illness.
Make adult care workable between visits
Include fatigue, sleep, mood, physical activity, employment, treatment burden and affordability in follow-up. Ask about missed doses without blame. Specify who orders tests, who reviews results, when reassessment occurs and how the patient obtains help for a changing pattern.
Discuss reproductive plans before an urgent medication decision is needed. Disease activity and medication exposure both matter. The EULAR reproductive update considers colchicine compatible with pregnancy and breastfeeding; other decisions depend on the individual agent and circumstances. Coordinate rheumatology, obstetric and other specialist advice when appropriate. Genetic counseling must distinguish inherited germline disease from acquired somatic conditions such as VEXAS.
Keep pediatric care distinct and plan transition
Pediatric autoinflammatory disease is a separate clinical field. This adult-focused collection provides only concentrated pediatric key points, including growth, development, family support and specialist assessment. Adult algorithms and dosing should not be transferred automatically to children.
Transition is a process, not a birthday or a referral letter. Identify an adult receiving team, prepare a concise medical summary, reconcile medicines and preserve access to prescriptions and monitoring. The handoff should include molecular reports, major organ involvement, prior MAS, treatment failures, allergies and an emergency plan. Confirm the first adult appointment and follow up missed attendance. Build practical self-management skills while adjusting family involvement to readiness and preferences. Use the transition chapter and the multilingual patient essentials to support shared planning.
Sources and further reading
- EULAR/ACR: diagnosis, management and monitoring of CAPS, TRAPS, MKD and DIRA (2021 points to consider; published 2022)
- EULAR/PReS recommendations for FMF: 2024 update (published 2025)
- EULAR/PReS recommendations for Still’s disease (2024)
- ACR international guidance on VEXAS. Arthritis Rheumatol. 2026;78:509–522; online 2025
- GeneReviews: VEXAS syndrome (2025)
- Schnitzler syndrome: diagnosis, treatment and follow-up (2013)
- Adult undifferentiated autoinflammatory disease and PFAPA: clinical cohort (2024)
- International consensus on DADA2 (2023)
- GeneReviews: haploinsufficiency of A20 (2024)
- MAS classification criteria in systemic JIA (2016)
- Development and validation of the HScore (2014)
- EULAR recommendations on antirheumatic drugs in reproduction: 2024 update (published 2025)
- ACR guideline for vaccination in rheumatic disease (2022)
- EULAR/PReS standards for transition from pediatric to adult rheumatology (2017)
- Histiocyte Society recommendations for HLH in adults (2019)
- Eurofever/PRINTO classification criteria for autoinflammatory recurrent fevers (2019)